| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785574P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068653WO2020139992A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| Publication Number | Publication Date |
|---|---|
| PE20212303A1true PE20212303A1 (es) | 2021-12-10 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001090APE20212303A1 (es) | 2018-12-27 | 2019-12-27 | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer |
| Country | Link |
|---|---|
| US (1) | US20220098203A1 (es) |
| EP (1) | EP3902804A1 (es) |
| JP (1) | JP2022516882A (es) |
| KR (1) | KR20220050832A (es) |
| CN (1) | CN113474347A (es) |
| AR (1) | AR115296A1 (es) |
| AU (1) | AU2019414446A1 (es) |
| BR (1) | BR112021012599A2 (es) |
| CA (1) | CA3124678A1 (es) |
| CL (1) | CL2021001722A1 (es) |
| CO (1) | CO2021009882A2 (es) |
| CR (1) | CR20210409A (es) |
| EA (1) | EA202191800A1 (es) |
| IL (1) | IL284324A (es) |
| JO (1) | JOP20210171A1 (es) |
| MA (1) | MA54609A (es) |
| MX (1) | MX2021007833A (es) |
| PE (1) | PE20212303A1 (es) |
| PH (1) | PH12021551493A1 (es) |
| SG (1) | SG11202106627WA (es) |
| TW (1) | TW202039489A (es) |
| WO (1) | WO2020139992A1 (es) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| JOP20210172A1 (ar)* | 2018-12-27 | 2023-01-30 | Les Laboratoires Servier Sas | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان |
| WO2021219731A2 (en)* | 2020-04-28 | 2021-11-04 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and uses thereof |
| IL297879A (en)* | 2020-06-22 | 2023-01-01 | Hoffmann La Roche | Amidopyrimidone derivatives |
| CN115960098A (zh)* | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| WO2022143864A1 (zh)* | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
| WO2022206730A1 (zh)* | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| CA3241698A1 (en)* | 2021-12-21 | 2023-06-29 | Changyou MA | Methionine adenosyltransferase 2a heterocyclic inhibitor |
| KR20240138099A (ko)* | 2022-01-26 | 2024-09-20 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제 |
| CN118742550A (zh)* | 2022-03-11 | 2024-10-01 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
| CN118900841A (zh) | 2022-06-27 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 三环类化合物及其用途 |
| TW202415370A (zh) | 2022-10-13 | 2024-04-16 | 南韓商韓美藥品股份有限公司 | 新穎三環衍生物化合物以及其應用 |
| WO2024183778A1 (zh)* | 2023-03-06 | 2024-09-12 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| WO2024255805A1 (zh)* | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的晶型、其制备方法及用途 |
| WO2025000265A1 (en)* | 2023-06-28 | 2025-01-02 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds usefull as sos1 inhibitor |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| AU769989B2 (en)* | 1998-10-23 | 2004-02-12 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
| RU2265606C2 (ru)* | 1999-10-21 | 2005-12-10 | Ф.Хоффманн-Ля Рош Аг | ГЕТЕРОАЛКИЛАМИНОЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ГЕТЕРОЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ р38 |
| PA8577501A1 (es)* | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| US7084270B2 (en)* | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US7129351B2 (en)* | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| CN100497339C (zh)* | 2003-04-10 | 2009-06-10 | 霍夫曼-拉罗奇有限公司 | 嘧啶并化合物 |
| US7897762B2 (en)* | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| AU2008266883B2 (en) | 2007-06-20 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CN104418860B (zh)* | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
| MX390277B (es)* | 2016-08-31 | 2025-03-20 | Servier Lab | Inhibidores de procesos metabolicos celulares. |
| CN109384790B (zh)* | 2017-08-08 | 2022-05-10 | 药捷安康(南京)科技股份有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
| EA202092320A1 (ru)* | 2018-03-30 | 2021-03-09 | Аджиос Фармасьютикалз, Инк. | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли |
| Publication number | Publication date |
|---|---|
| CL2021001722A1 (es) | 2022-02-18 |
| EP3902804A1 (en) | 2021-11-03 |
| IL284324A (en) | 2021-08-31 |
| AU2019414446A1 (en) | 2021-07-15 |
| CN113474347A (zh) | 2021-10-01 |
| KR20220050832A (ko) | 2022-04-25 |
| PH12021551493A1 (en) | 2022-04-11 |
| JOP20210171A1 (ar) | 2023-01-30 |
| MX2021007833A (es) | 2021-10-26 |
| BR112021012599A2 (pt) | 2021-09-08 |
| SG11202106627WA (en) | 2021-07-29 |
| JP2022516882A (ja) | 2022-03-03 |
| MA54609A (fr) | 2022-04-06 |
| US20220098203A1 (en) | 2022-03-31 |
| AR115296A1 (es) | 2020-12-16 |
| TW202039489A (zh) | 2020-11-01 |
| CO2021009882A2 (es) | 2021-10-29 |
| CR20210409A (es) | 2022-01-24 |
| WO2020139992A1 (en) | 2020-07-02 |
| CA3124678A1 (en) | 2020-07-02 |
| EA202191800A1 (ru) | 2021-09-13 |
| Publication | Publication Date | Title |
|---|---|---|
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| DOP2022000039A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| ZA202102999B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| PE20220387A1 (es) | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| SV2017005384A (es) | Compuestos aminopirimidinilo | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| PE20212329A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer |